The Food and Drug Administration last week removed the requirement for a positive COVID-19 test result to prescribe Paxlovid to certain adult and pediatric patients and Lagevrio to certain adults at risk of progressing to severe COVID-19. The agency continues to recommend that health care providers use direct SARS-CoV-2 viral testing to help diagnose COVID-19, but said it recognizes that providers may in rare instances diagnose COVID-19 in patients with a negative test result but symptoms and a recent known exposure to COVID-19. For more information, see the updated Paxlovid and Lagevrio fact sheets for health care providers.

Related News Articles

Headline
The Centers for Disease Control and Prevention Dec. 11 released a report that found last year’s version of the COVID-19 vaccine was 76% effective in preventing…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
 The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…